Owlet stock hits 52-week low at $3.20 amid market challenges

Published 04/04/2025, 20:42
Owlet stock hits 52-week low at $3.20 amid market challenges

In a challenging market environment, Owlet Inc. (OWLT) has seen its stock price touch a 52-week low, dipping to $3.20. The company, known for its innovative health technology for infants, has faced a tough year, with its stock price reflecting a significant downturn. According to InvestingPro data, while the company maintains a healthy balance sheet with more cash than debt and impressive revenue growth of 44.5% in the last twelve months, it faces profitability challenges with negative EBITDA of -$18M. Over the past year, Owlet’s stock has experienced a decline of 20.24%, mirroring the struggles of Sandbridge Acquisition and other companies in the sector. Investors are closely monitoring the company’s performance for signs of a turnaround, even as it grapples with the pressures that have led to this year-long downward trend. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets significantly above current levels. Discover more insights and 6 additional ProTips for OWLT with an InvestingPro subscription.

In other recent news, Owlet Inc. reported a notable 37% increase in revenue for Q4 2024, reaching $20.5 million, and a full-year revenue of $78.1 million, marking a 45% rise from the previous year. The company’s gross margin also improved significantly to 53.5% in Q4, contributing to a full-year margin of 50.4%. Owlet launched its Owlet360 subscription service in January 2025, already attracting over 25,000 subscribers. The company projects 2025 revenue between $88 million and $92 million, with gross margins expected to range from 50% to 52%. Owlet aims for adjusted EBITDA profitability by focusing on increasing DreamSock adoption and expanding its medical channels. Additionally, the company is expanding its presence in medical and healthcare channels with its FDA-cleared BabySat device, targeting higher-risk infants. Owlet has also made strides in international markets, with Q4 2024 international revenue growing by 45% year-over-year. These developments indicate Owlet’s strategic focus on growth and operational efficiency in the pediatric health monitoring market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.